Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

High-Risk Hodgkin Lymphoma and BV+Nivolumab After HSCT

admin by admin
March 20, 2023
in News


The following is a summary of “Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial” published in the January, 2023 issue of Haematology by Herrera, et al.


In high-risk relapsed or refractory classic Hodgkin lymphoma patients, consolidation with brentuximab vedotin following autologous hematopoietic stem-cell transplantation (HSCT) improves progression-free survival compared to placebo. Researchers tested brentuximab vedotin and nivolumab in high-risk recurrent or refractory classic Hodgkin lymphoma patients post-autologous HSCT. Five US sites hosted phase 2 experiments. All patients were 18 or older, had high-risk relapsed or refractory classic Hodgkin lymphoma, an ECOG performance level of 0-2, and acceptable organ and bone marrow function to be included. Participants received intravenous brentuximab vedotin (1/8 mg/kg) and nivolumab (3 mg/kg) on day 1 of each 21-day cycle for a maximum of 8 cycles starting 30-60 days following autologous HSCT.

Nivolumab dosage could not be reduced. 0.5 mg/kg of brentuximab vedotin is possible. If the consumption of one drug is stopped due to toxic effects, the other can still be taken. All patients’ primary outcome was 18-month progression-free survival. Between May 3, 2017, and July 13, 2019, 59 people were registered and treated. Patients received a median of 8 cycles of brentuximab vedotin with nivolumab after 54 days (IQR 46-58) post-autologous HSCT (8–8). 34 (58%) of 59 patients were male; 29 (49%) completed all 8 cycles of brentuximab vedotin + nivolumab; 45 (76%) completed at least one drug. Follow-up averaged 29.9 months (interquartile range, 24.6-34.8). All 59 patients had 94% (95% CI 84-98) progression-free survival after 18 months.

About 17 [29%] of 59 patients required corticosteroids due to immune-related side effects, along with neutropenia (25 [42%]) and peripheral sensory neuropathy (31 [53%]). Treatment caused no deaths. Post-autologous HSCT patients with high-risk relapsed or refractory classic Hodgkin lymphoma responded well to brentuximab vedotin and nivolumab. Combination immunotherapy for typical Hodgkin lymphoma needs further study to reduce side effects, especially in high-risk patients who need more intensive treatment to avoid relapse.

The study was funded by Myers Squibb, the Leukaemia and Lymphoma Society, the Lymphoma Research Foundation, and the National Cancer Institute of the National Institutes of Health.

Source: thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00318-0/fulltext



Source link

Advertisement Banner
Previous Post

Travel nurse pay remains high as states debate payment caps

Next Post

Microsoft’s Nuance adds ChatGPT successor GPT-4 to EHR

Related Posts

News

Understanding the Progression of Very Early-Onset Inflammatory Bowel Disease: A Clinical Perspective

June 5, 2023
News

ASCO: Phone-Based Coaching Helps Breast Cancer Patients Lose Weight

June 4, 2023
News

Double Dissociation of Orientation & Brightness Judgments: Investigating Visual Crowding Effects

June 3, 2023
News

Strategies for Enhancing Workforce Representation

June 2, 2023
News

Factors Associated with Recurrences or Relapses in Individuals Diagnosed with GCA

June 1, 2023
News

Examining Independently Billed Dermatologic Procedures by Nonphysician Practitioners in the US

May 31, 2023
Next Post

Microsoft's Nuance adds ChatGPT successor GPT-4 to EHR

Recommended

20 Questions You’ll Want To Know About the NCLEX

1 month ago

Association of Health Care Journalists ends relationship with University of Missouri School of Journalism

4 weeks ago

THCB Gang Episode 108, Thursday December 1, 1pm PT – 4p – The Health Care Blog

6 months ago

How to Distinguish Respiratory Distress from Failure

6 months ago

Health Gorilla & Interoperability’s New TEFCA-Fueled Future – The Health Care Blog

6 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.